UBS Maintains a 'Buy' on Perrigo Co. (PRGO); Highlights From Meeting with CEO

March 5, 2012 11:37 AM EST
Get Alerts PRGO Hot Sheet
Price: $12.82 -1.69%

Rating Summary:
    12 Buy, 14 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 12 | Down: 23 | New: 22
Join SI Premium – FREE
UBS maintains a 'Buy' on Perrigo Co. (NASDAQ: PRGO) price target raised from $115 to $120.

UBS analyst says, "We hosted an investor lunch with Perrigo’s CEO Joe Papa - Key highlights were: (1) Mgt. believes that a better understanding of risk factors for hyperlipidemia and FDA’s renewed commitment to expand access to low cost drugs has made it more feasible than before for categories like statins to switch from Rx-to-OTC; raising its probability from 50% to ~65%; (2) That said, FDA is still early in the process and new switch categories are still a few years away...Add’l highlights: Key topics were Rx-to-OTC switches and OUS growth."

"Near term, we remain committed to the name as a core holding in pharma based on its high double digit organic EPS growth potential and business development strategy."

For an analyst ratings summary and ratings history on Perrigo Co. click here. For more ratings news on Perrigo Co. click here.

Shares of Perrigo Co. closed at $105.80 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst PT Change

Related Entities

UBS